Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)

计划入组 448 人 · 首次发布于 2019 年 4 月 23 日

Study Evaluating HTC-867 in Healthy Young and Elderly Subjects

计划入组 72 人 · 首次发布于 2009 年 1 月 22 日

Study Evaluating The Safety and Tolerability of HTC-867 in Healthy Japanese Subjects

计划入组 56 人 · 首次发布于 2010 年 12 月 29 日

MDPC-867

HTC-867

NSD-867

Nitric Oxide Innovations LLC

United States

Holly University Obgyn Department

United States

THE OHIO STATE UNIVERSITY

United States

Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC

KEYNOTE-867: Pembrolizumab Plus SBRT Fails to Improve Survival in Early-Stage NSCLC

Keytruda Fails in Phase 3 Trials for Early-Stage Lung and Skin Cancer